NEW YORK – Myriad Genetics on Monday announced plans to expand access to its myChoice CDx in Europe and China.
In China, Myriad signed a development and commercial agreement with Burning Rock Biotech to use its myChoice homologous recombination deficiency (HRD) test in Phase III drug development studies and in clinics.